GRANULES INDIA
GenericsGRANULES INDIA is a generic drug manufacturer focused on Immunology.
GRANULES INDIA's Key Drugs
GRANULES INDIA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
GRANULES INDIA's Recent FDA Approvals
New NDA/BLA approvals for GRANULES INDIA over the last two years — novel drugs only, excluding generics and label supplements.
GRANULES INDIA's Therapeutic Areas
GRANULES INDIA's approved drugs and pipeline span 1 therapeutic area, led by Immunology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
GRANULES INDIA's Top Competitors
GRANULES INDIA's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and AbbVie. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
GRANULES INDIA Pipeline Snapshot
Active clinical trials for GRANULES INDIA across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Immunology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2010-04-22
- Latest
- 2025-11-10
- Applications
- 4